A Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Dose Study to Evaluate and Compare the Pharmacokinetics of ER OROS Paliperidone in Healthy Japanese and Caucasian Subjects.
Phase of Trial: Phase I
Latest Information Update: 31 Mar 2010
At a glance
- Drugs Paliperidone (Primary)
- Indications Bipolar disorders; Schizoaffective disorder; Schizophrenia
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Janssen Research & Development
- 10 Jun 2017 Biomarkers information updated
- 31 Mar 2010 Actual number of patients added to 60 as reported by ClinicalTrials.gov.
- 04 Oct 2008 New trial record.